Apolipoprotein E (APOE) - Pipeline Review, H2 2016

  • ID: 3961163
  • Drug Pipelines
  • 39 pages
  • Global Markets Direct
1 of 5
Apolipoprotein E (APOE) - Pipeline Review, H2 2016

‘Apolipoprotein E (ApoE) - Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
- Certain sections in the report may be removed or altered based on the availability and relevance of data.
- Updated report will be delivered in 48 hours of order confirmation.

Scope:

- The report provides a snapshot of the global therapeutic landscape for Apolipoprotein E (ApoE)
- The report reviews Apolipoprotein E (ApoE) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Apolipoprotein E (ApoE) targeted therapeutics and enlists all their major and minor projects
- The report assesses Apolipoprotein E (ApoE) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Apolipoprotein E (ApoE) targeted therapeutics

Reasons to Buy:

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Apolipoprotein E (ApoE)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Apolipoprotein E (ApoE) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Apolipoprotein E (APOE) Overview

Therapeutics Development

Apolipoprotein E (APOE) - Products under Development by Stage of Development

Apolipoprotein E (APOE) - Products under Development by Therapy Area

Apolipoprotein E (APOE) - Products under Development by Indication

Apolipoprotein E (APOE) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Apolipoprotein E (APOE) - Products under Development by Companies

Apolipoprotein E (APOE) - Products under Development by Universities/Institutes

Apolipoprotein E (APOE) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Apolipoprotein E (APOE) - Companies Involved in Therapeutics Development

LipimetiX Development Inc

Apolipoprotein E (APOE) - Drug Profiles

AEM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2814 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target ApoE for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant ApoE4 for Dyslipidemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate ApoE for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Apolipoprotein E (APOE) - Featured News & Press Releases

Oct 14, 2015: Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides

Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

Dec 16, 2014: Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals

Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects

Jun 05, 2014: ApoE Immunotherapy and Prions Advance in Alzheimer’s Research

Apr 08, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction

Nov 19, 2013: Capstone Therapeutics Announces a LipimetiX Development Presentation at the American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit of AEM-28 on Established Atherosclerotic Lesions

Dec 06, 2012: Capstone Therapeutics's Partner LipimetiX Obtains Orphan Drug Designation For AEM-28 To Treat Homozygous Familial Hypercholesterolemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by LipimetiX Development Inc, H2 2016

List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- LipimetiX Development Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll